|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 6408 |
FusionGeneSummary for CDC73_TROVE2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CDC73_TROVE2 | Fusion gene ID: 6408 | Hgene | Tgene | Gene symbol | CDC73 | TROVE2 | Gene ID | 79577 | 6738 |
| Gene name | cell division cycle 73 | TROVE domain family member 2 | |
| Synonyms | C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX | RO60|RORNP|SSA2 | |
| Cytomap | 1q31.2 | 1q31.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | parafibrominPaf1/RNA polymerase II complex componentcell division cycle 73 Paf1/RNA polymerase II complex component-like proteincell division cycle 73, Paf1/RNA polymerase II complex component, homologcell division cycle protein 73 homologhyperparath | 60 kDa SS-A/Ro ribonucleoprotein60 kDa ribonucleoprotein RoSjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)gastric cancer multi-drug resistance proteinsjoegren syndrome type A antigen | |
| Modification date | 20180523 | 20180519 | |
| UniProtAcc | Q6P1J9 | P10155 | |
| Ensembl transtripts involved in fusion gene | ENST00000367435, ENST00000477868, | ENST00000400968, ENST00000432079, ENST00000460715, ENST00000416058, ENST00000367446, ENST00000367445, ENST00000367444, ENST00000367443, ENST00000367441, | |
| Fusion gene scores | * DoF score | 5 X 4 X 5=100 | 3 X 3 X 2=18 |
| # samples | 5 | 4 | |
| ** MAII score | log2(5/100*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/18*10)=1.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: CDC73 [Title/Abstract] AND TROVE2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CDC73 | GO:0008285 | negative regulation of cell proliferation | 16989776 |
| Hgene | CDC73 | GO:0010390 | histone monoubiquitination | 16307923 |
| Hgene | CDC73 | GO:0030177 | positive regulation of Wnt signaling pathway | 16630820 |
| Hgene | CDC73 | GO:0032968 | positive regulation of transcription elongation from RNA polymerase II promoter | 20178742 |
| Hgene | CDC73 | GO:0033523 | histone H2B ubiquitination | 16307923 |
| Hgene | CDC73 | GO:0045638 | negative regulation of myeloid cell differentiation | 20541477 |
| Hgene | CDC73 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 20178742 |
| Hgene | CDC73 | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 16989776 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | LIHC | TCGA-BC-A10T-01A | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000367435 | ENST00000400968 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000432079 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000460715 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000416058 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000367446 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000367445 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000367444 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-3UTR | ENST00000367435 | ENST00000367443 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| 5CDS-intron | ENST00000367435 | ENST00000367441 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000400968 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000432079 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000460715 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000416058 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000367446 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000367445 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000367444 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-3UTR | ENST00000477868 | ENST00000367443 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
| intron-intron | ENST00000477868 | ENST00000367441 | CDC73 | chr1 | 193121574 | + | TROVE2 | chr1 | 193060781 | + |
Top |
FusionProtFeatures for CDC73_TROVE2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CDC73 | TROVE2 |
| Tumor suppressor probably involved in transcriptionaland post-transcriptional control pathways. May be involved in cellcycle progression through the regulation of cyclin D1/PRAD1expression. Component of the PAF1 complex (PAF1C) which hasmultiple functions during transcription by RNA polymerase II andis implicated in regulation of development and maintenance ofembryonic stem cell pluripotency. PAF1C associates with RNApolymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms andis involved in transcriptional elongation, acting bothindepentently and synergistically with TCEA1 and in cooperationwith the DSIF complex and HTATSF1. PAF1C is required fortranscription of Hox and Wnt target genes. PAF1C is involved inhematopoiesis and stimulates transcriptional activity ofKMT2A/MLL1; it promotes leukemogenesis through association withKMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histonemodifications such as ubiquitination of histone H2B andmethylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits theRNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzymeUBE2A or UBE2B to chromatin which mediate monoubiquitination of'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2Bubiquitination is proposed to be coupled to transcription. PAF1Cis involved in mRNA 3' end formation probably through associationwith cleavage and poly(A) factors. In case of infection byinfluenza A strain H3N2, PAF1C associates with viral NS1 protein,thereby regulating gene transcription. Connects PAF1C with thecleavage and polyadenylation specificity factor (CPSF) complex andthe cleavage stimulation factor (CSTF) complex, and with Wntsignaling. Involved in polyadenylation of mRNA precursors.{ECO:0000269|PubMed:15580289, ECO:0000269|PubMed:15632063,ECO:0000269|PubMed:15923622, ECO:0000269|PubMed:16630820,ECO:0000269|PubMed:16989776, ECO:0000269|PubMed:19136632,ECO:0000269|PubMed:19952111, ECO:0000269|PubMed:20178742,ECO:0000269|PubMed:20541477, ECO:0000269|PubMed:21329879}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CDC73_TROVE2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for CDC73_TROVE2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| CDC73 | ANXA6, HSPA4, PITHD1, KCNH2, GC, WWC1, RANBP2, CTR9, LEO1, PAF1, POLR2A, CDK9, MEPCE, KMT2A, CPSF1, CPSF2, CPSF3, RRAGA, CSTF2, KMT2C, ASH2L, RBBP5, CPSF4, CSTF3, TCEA1, RTF1, MCM3AP, DDAH2, HAP1, CEP70, HSF2BP, ITFG1, FAF1, RNF20, RNF40, HSP90AA1, WDR61, HIST1H3A, PTPN11, CTNNB1, SUV39H1, GTF2F1, BCL9L, SOX2, DNMT3A, DNMT3B, ARFGEF2, CHUK, COG3, MYH14, NUP98, MYH9, MYL12A, GPRASP2, CIAO1, AURKB, ALAS1, GOLGA2, TFCP2, MTUS2, VPS37B, TSGA10, FSD2, CCDC155, HIST1H1A, HIST1H1C, NTRK1, AP3B1, AP3D1, AP3S1, SRRM2, NUMA1, TCF7L2, KRAS, XPO1, RAD51, TCEB2, BRPF1, SCAMP3, UQCRQ, IMPACT, MRPS15, CD44, POLR2G, RFX5, SUPT5H, AP4S1, CNTROB, C1orf131, MYC, SNW1, CDC5L, NANOG, HIST2H2BE, HIST3H3, PDIA6, DHRS2, LANCL1, ANP32B, CCT4, CCT2, PAICS, GNA13, CCT8, CFL1, RAB10, YWHAQ, DCD, CLTC, CNN3, MYO3B, RAB40A, CSE1L, DSG1, DSP, EEF1A1, EEF1A2, EEF1D, EEF1G, EEF2, EIF2S1, EIF2S3, ENO1, EPRS, ALB, ALCAM, ALDOA, FKBP4, CCT5, ERP44, FLNA, FLNB, FLNC, EXOC7, G6PD, GAPDH, PHGDH, FBXO3, RAB30, GNA12, SFN, RAB40AL, CCDC88B, ANXA1, ANXA2, HADHA, HK1, HNRNPF, HNRNPK, HSD17B4, DNAJA1, HSPA2, HSPA5, HSPA8, HSPA9, HSPB1, HSP90AB1, HSPD1, TUBB8, ITGB1, JUP, KARS, ARF1, ARF3, ARF4, FLG2, RPSA, LDHA, RAB8A, MIF, POTEE, MSN, MTHFD1, NEFH, NNMT, NUCB2, ATP5A1, PRDX1, ATP5B, PCBP1, PCNA, SAR1B, PFN1, PGD, PKM, PLG, PCBP3, PPA1, PRKDC, PRSS1, PSMC2, PSMD2, RAB1A, RAB2A, RAB5A, RAB5C, RAN, RARS, RNH1, RPL7, RPL11, RPL22, RPLP0, RPN1, RPN2, RPS3, RPS5, RPS10, RPS17, RPS27A, SLC3A2, SNRPA1, TCP1, TFRC, HSP90B1, CCT3, UBA52, UBB, UBC, VCP, VIM, YWHAB, YWHAE, YWHAZ, ACTN4, CALR, SLC7A5, HM13, RAB1B, CANX, CLTCL1, CAPZB, TAGLN2, ACTN1, GBF1, CCT6A, CAND1, CUL1, UBA1, FBXO21, RUVBL2, TULP2, ERMAP, CHEK2, CHEK1, TOP1, TOP2A, TOP3A, DHFR, WEE1, IMPDH1, TUBA1A, NCL, G3BP1, UHRF2, TES | TROVE2 | PUF60, CUL3, TRIM21, SSB, TEP1, PAGR1, METTL18, CARS, GFPT1, HIRIP3, RPL24, SF1, FAF1, GARS, GART, HIST1H4A, HSPA4, JMJD6, PPAT, PPM1G, PRMT3, RANBP3, SEC23A, UGP2, XPO7, UNK, ATL3, SUB1, UQCRQ, NTRK1, RNY3, RNY1, DUSP12, ELAVL2, RBM3, UBE2A |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CDC73_TROVE2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for CDC73_TROVE2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CDC73 | C1840402 | HYPERPARATHYROIDISM 1 | 3 | CTD_human;ORPHANET;UNIPROT |
| Hgene | CDC73 | C1704981 | Hyperparathyroidism-Jaw Tumor Syndrome | 1 | CTD_human;ORPHANET;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|